Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...

For tissues to cooperate and perform normal functions, cells need to know which way is up. When cells lose track of their orientation, they can start to grow out of control, and develop into cancer.

Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.

The order of cancer-driving mutations—genetic changes—plays an important role in whether tumors in the intestine can develop, new research reveals. Subscribe to our newsletter for the latest sci-tech ...

Pancreatic cancer is a rare disease; however, its initially inconspicuous symptoms and aggressive nature make it one of the deadliest forms of cancer.

Human papillomavirus (HPV) can drive tumor development in some rare sinonasal squamous cell carcinomas (SNSCCs), according to a new comprehensive study of these tumors from investigators at the Johns ...

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, ...

Janux Therapeutics, Inc. (Nasdaq: JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor ...

When you think about brain tumors, you might assume they’re purely a matter of bad genetic luck or something that happens to “other people.” But emerging research suggests that various factors in our ...